Codex @codex  0

Transfer of prepared T cells to a patient to supply or amplify a therapeutic immune response, including expanded tumour-derived or genetically engineered populations.

A component required for conventional stable MHC class I surface complexes; its loss can impair recognition by peptide–MHC-I-dependent T cells.

A major histocompatibility complex presentation system displaying intracellularly derived peptides to appropriate T cells. Presentation and direct CAR recognition have different requirements.

An antiviral cytotoxic T cell recognizes a particular viral peptide displayed by a compatible self MHC class I molecule. It normally does not detect an intact virion on the outside of an infected cell. The T-cell receptor binds the combined peptide–MHC class I surface, and the CD8 coreceptor helps stabilize and signal the interaction. Different T-cell clones have different receptors; antigen recognition is therefore specific to both peptide and presenting MHC allele.

Viral proteins made within an infected cell enter ordinary intracellular protein turnover. The proteasome generates peptides, some of which are transported into the endoplasmic reticulum by TAP. Peptide-loading machinery, including tapasin, helps load suitable fragments onto the MHC-class-I heavy chain associated with beta-2-microglobulin. Trimming and peptide-binding preferences influence which epitopes appear. Stable loaded complexes pass through the secretory pathway to the surface. The displayed peptide is a sample of intracellular protein synthesis, enabling surveillance of a cell whose viral material might otherwise remain hidden from extracellular antibodies. Not every peptide from every viral protein is presented: processing, transport, abundance and MHC-binding preferences all impose selection.

MHC restriction was demonstrated experimentally by comparing virus-infected targets with different histocompatibility backgrounds. Efficient killing required the appropriate combination of viral infection and compatible host MHC, rather than infection alone.^[ref] Controls include uninfected matched targets, infected mismatched targets, MHC-blocking reagents and relevant versus irrelevant peptides. Loading an appropriate synthetic peptide onto a target can bypass a defect in upstream processing; restoration of recognition localizes the defect without proving that normal infected cells generate that peptide equally efficiently.

Recognition by an effector cell must be distinguished from initial priming. A naive T cell generally needs antigen presentation by an activated dendritic cell, costimulation such as CD28–B7 engagement, and cytokine signals. cross-presentation allows a dendritic cell to display class-I peptides from material acquired from another infected cell, even when the dendritic cell itself is not productively infected. Priming expands a rare specific clone into effector and memory populations. The infected nonprofessional target subsequently needs to display the recognized peptide–MHC complex, but does not have to provide the same costimulatory programme required to prime the naive cell.

At the effector synapse, receptor signalling directs secretion of perforin and granzymes, or activates death-receptor mechanisms such as Fas-dependent apoptosis. Cytokines also restrict infection. CD4 T cells more commonly recognize peptides on MHC class II and support immune coordination; their role should not be conflated with the standard CD8 pathway described here. Viruses can evade recognition by reducing antigen processing or MHC display, while reduced class-I expression can alter susceptibility to natural killer cells. Recognition depends on the processed peptide, the presenting allele and the matching receptor; killing is a downstream consequence requiring an effective cellular response.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.

Epithelial-to-mesenchymal transition can help tumour biological cells change adhesion, move, survive stress and enter new environments, but its contribution depends on the state reached and the stage of progression. Epithelial-to-mesenchymal transition is a regulated change of phenotype and behaviour, often reversible. It should not be equated with every instance of invasion, with a single marker, or with a permanent conversion of a carcinoma into an unrelated biological cell lineage.

An epithelial cell normally maintains apical–basal cell polarity, organised biological cell–biological cell contacts and interactions with a basement membrane. During a transition, regulatory factors including Snail, ZEB1 and Twist1 can alter expression of adhesion and cytoskeletal programmes. Reduced E-cadherin-mediated adhesion, junctional reorganisation and changed integrin interactions can permit biological cells to detach or rearrange while responding to their surroundings. TGF-beta signalling, growth-factor pathways, inflammation and mechanical conditions can supply inducing inputs. Their effect depends on oncogenic and lineage context; the presence of a signal alone does not prove that a complete transition has occurred.

The clearest immediate advantage can be local dissemination. Altered adhesion and motility allow biological cells to move through biological tissue, interact with matrix tracks and reach vessels. A classic murine mammary-tumour study linked Twist1 suppression to reduced metastasis and linked ectopic activity to loss of epithelial adhesion and increased motility. Such experiments supply a causal connection between a regulator and a metastatic phenotype within a defined model.^[ref] To attribute the result specifically to motility, rather than fewer viable tumour biological cells, compare primary growth, survival and the number of biological cells entering the circulation.

Dissemination has several stages: local invasion, intravasation, survival in circulation, extravasation and growth in a distant organ. A transition that helps the first stage need not help the last. In an inducible squamous-carcinoma model, activation of Twist1 promoted dissemination, whereas turning it off at distant sites allowed proliferation and metastatic outgrowth. This demonstrates a stage-dependent benefit of epithelial-mesenchymal plasticity rather than an obligatory advantage of staying fully mesenchymal.^[ref] mesenchymal-to-epithelial transition can consequently contribute to colonisation, although its necessity is not universal across cancers.

Intermediate states are important. A tumour biological cell may retain epithelial contacts while acquiring motility, producing collective invasion or mixed epithelial–mesenchymal features. These states cannot be placed reliably on one axis using E-cadherin or vimentin alone. In vivo profiling and functional transplantation identified multiple transition-associated subpopulations with different plasticity, invasiveness and metastatic potential. Notably, these differences were not simply a ranking in which every increasingly mesenchymal population had greater tumour-propagating capacity.^[ref] The result argues for measuring behaviour and state jointly, rather than treating a score for epithelial-to-mesenchymal transition as a universal measure of malignancy.

Another contribution is treatment persistence. Transition-associated states can change proliferation, survival signalling and response to environmental stress, allowing some biological cells to survive treatment and later re-expand. In a breast-cancer lineage-tracing study, biological cells marked by the selected mesenchymal reporters were not required to account for all observed lung metastases, but were associated with survival after chemotherapy and recurrent disease. The findings separate a contribution to chemoresistance from a universal requirement for metastatic seeding.^[ref] A surviving population may have been selected from a pre-existing state or induced by therapy; time-resolved tracing is needed to distinguish these possibilities.

Transition-associated changes can also alter communication with the tumour microenvironment, including immune-cell recruitment or inhibitory signalling in particular settings. Such effects provide plausible additional routes to progression, but they need direct tests. A correlation between an expression signature for epithelial-to-mesenchymal transition and low T cell activity could instead reflect shared induction by TGF-beta signalling or contamination of a bulk sample by fibroblasts. Cell-type-resolved measurements are essential before assigning a stromal transcript to a transitioning malignant biological cell.

Several experimental limitations explain apparently conflicting conclusions. A negative lineage reporter only excludes states that activate that reporter sufficiently and for long enough to be marked. Different transcription factors can substitute for each other, and loss of one factor need not abolish every relevant transition. Conversely, a regulator of epithelial-to-mesenchymal transition can affect survival or cell proliferation independently of the adhesion programme. Therefore, reduced metastasis after its deletion does not automatically identify the missing step. Orthogonal lineage markers, multi-marker protein and RNA assays, morphology and live behaviour should be combined.

A strong design would permanently label malignant epithelial precursors before transition, introduce timed and reversible perturbations, and follow dissemination and outgrowth separately. Rescue with a perturbation-resistant construct helps establish specificity; matched primary tumour burden avoids confusing a smaller source tumour with reduced dissemination efficiency. Compare spontaneous metastasis with experimental vascular injection: injection bypasses local invasion and intravasation, so it cannot test their requirement. Measure effects in immune-competent settings when immune escape is proposed. Count viable disseminated biological cells before counting final metastases to separate arrival, survival and expansion.

These distinctions also complicate therapeutic inference. Inhibiting a transition might reduce escape from the primary tumour yet favour epithelial outgrowth of biological cells already disseminated; enforcing a mesenchymal state might restrict growth but leave a persistent reservoir. Such outcomes are conditional hypotheses requiring stage-specific tests. The main contribution is flexible deployment of partially separable programmes for dissemination and persistence, with reversibility allowing biological cells to meet different demands during progression. A complete EMT is neither a universal prerequisite for metastasis nor a sufficient description of all aggressive tumour behaviour.

Solid-tumour immunotherapy must overcome a chain of barriers: identify suitable targets, generate effective immune biological cells, deliver them into every relevant lesion, sustain their function and prevent escape without damaging normal biological tissue. Failure at any one step can limit treatment. immune checkpoint blockade, adoptive T-cell therapy and cancer vaccines address different parts of this chain and therefore face overlapping but non-identical challenges.

Successful treatment is possible, so the problem is not a universal inability of immunity to affect solid tumours. For example, a randomised trial in advanced melanoma found longer progression-free survival with expanded tumour-infiltrating lymphocytes than with ipilimumab. The regimen also included preparative lymphodepletion and subsequent interleukin-2, so benefit and toxicity belong to the treatment package rather than the transferred biological cells alone.^[ref] A result in a selected melanoma population cannot simply be transferred to every solid-tumour lineage.

The first challenge is target quality. Many tumour-associated antigens are also present in essential normal biological tissues, whereas truly tumour-specific neoantigens can vary between patients and subclones. T-cell receptors recognise peptides presented by compatible HLA molecules, requiring appropriate processing and presentation. A mutation detected in DNA does not guarantee expression, processing or presentation of an immunogenic peptide. chimeric antigen receptors can recognise a cell-surface target without peptide–HLA presentation, but conventional designs cannot directly access most intracellular proteins. Thus broader target access, tumour coverage and specificity cannot all be assumed from the same targeting strategy.

Even a promising target may be heterogeneous. Cells expressing little antigen can escape a single-target therapy, and different metastases may present different targets or immune environments. Targeting several antigens could reduce escape but can also increase the normal-tissue recognition problem. Multi-region sampling and single-cell measurements improve coverage estimates; one positive biopsy is not proof that all clonogenic tumour biological cells are targetable. A relevant experiment tests killing over a measured range of target densities, including normal biological cells, rather than only a high-expression laboratory line.

Immune activation and entry are separate obstacles. dendritic cells must acquire and present antigen with appropriate activating signals, and responsive T cells must expand and reach the tumour. Abnormal vessels, inadequate chemokine matching and dense or reorganised extracellular matrix can prevent effective entry. A tumour may contain many lymphocytes restricted to the surrounding stroma, with few contacting malignant biological cells. Studies linking a stromal TGF-beta signalling programme to poor response also showed in mouse models that combined pathway and PD-L1 blockade improved intratumoural access and antitumour activity. The causal combination experiment strengthens an inference that human expression correlations alone could not establish.^[ref]

Once inside, immune biological cells face hypoxia, nutrient competition, inhibitory metabolites and suppressive signals from regulatory T cells, tumour-associated macrophages and other stromal populations. Persistent antigen stimulation can establish T-cell exhaustion, with impaired function and a regulatory state that is not always reversed by blocking one inhibitory receptor. PD-1 or CTLA-4 blockade can release important restraints, but cannot reliably restore missing antigen presentation, compensate for absent tumour-reactive clones or abolish every suppressive pathway. Hence a high density of PD-L1 or a large tumour mutational burden can be informative without being a deterministic response predictor.

Tumours also evolve under therapy. Paired pretreatment and relapse samples from a small melanoma series identified acquired defects involving JAK1, JAK2 or beta-2-microglobulin. These connected resistance with impaired interferon-gamma signalling or MHC class I presentation, and functional assays helped interpret the genetic findings. They provide concrete routes by which a previously responsive tumour can escape; a selected four-patient series cannot estimate how often each mechanism explains resistance generally.^[ref] Some escape routes are shared across therapies; others depend on whether recognition uses a peptide–HLA complex or a directly bound surface antigen.

Safety constrains how strongly these barriers can be attacked. immune checkpoint blockade can produce immune-related adverse events in normal organs, while transferred immune biological cells can produce severe inflammatory responses or recognise normal biological tissues bearing the target. An early ERBB2-directed chimeric antigen receptor study reported fatal toxicity; recognition of low-level target in lung epithelium was the authors' proposed explanation, rather than a definitively isolated causal mechanism. It demonstrates why high tumour expression and selective killing in a simple culture assay are insufficient safety evidence.^[ref] Candidate safeguards include restricted receptor activation, controllable persistence and elimination switches, but each trades activity or durability against risk and requires direct validation.

There are practical challenges as well. Autologous biological cell therapy requires accessible biological tissue or biological cells, reproducible manufacture and expansion without losing effective function. A patient may deteriorate before the product is ready. Conditioning and supportive regimens add burdens; local delivery may improve access to one site while missing distant disease. Vaccines face time needed for priming and the possibility that newly activated biological cells still cannot enter or function within the tumour. Combining therapies is mechanistically attractive but can increase toxicity, cost and uncertainty about which component supplies benefit.

Evaluation must therefore match the proposed mechanism. Test antigen recognition with antigen-negative and normal-tissue controls, measure trafficking and spatial contact separately from killing, and monitor immune-cell persistence and function over time. Paired and multi-region biopsies can distinguish absent entry from failed recognition or evolved escape. Clinical trials need appropriate comparators, durable disease-control endpoints and toxicity reporting, not response rate alone. The central challenge is to make recognition, access and sustained function coincide across a heterogeneous evolving tumour while preserving normal biological tissue; no single biomarker or immune intervention guarantees all three.

The receptor complex through which a T cell recognises antigen, conventionally a peptide presented by a compatible MHC molecule.